How to treat Lung cancer?

['Tega amatwi iyi paji']

Ni gute wavura kanseri y'ibihaha?

Kuvura kanseri y'ibihaha biterwa n'ibintu byinshi, harimo igihe kanseri igeze, ubwoko bwayo n'ubuzima bw'umurwayi muri rusange.

Bimwe mu byo abantu bakunze kwivuza harimo:

1. Kubagwa: Akenshi ni bwo buryo bwo kuvura kanseri y'ibihaha ikiri nto cyane bukunze gukoreshwa.

Umuganga ubaga akuramo ikibyimba n'utundi duce duto tw'umubiri tuba dukikije.

2. Imiti igabanya ubukana bw'indwara: Imiti igabanya ubukana bw'indwara ikoreshwa mu kwica ingirabuzimafatizo za kanseri no kugabanya ibibyimba.

Ishobora gukoreshwa yonyine cyangwa igafatanya n'indi miti.

3.Kimioterapiya: ubu buryo bwo kuvura bukoresha imiti yica ingirabuzimafatizo za kanseri.

Ishobora guterwa mu mutsi cyangwa mu kanwa, kandi akenshi ikoreshwa hamwe n'indi miti.

4. Kuvura kanseri: ubu buryo bwo kuvura bwibanda ku ngirabuzima fatizo cyangwa poroteyine runaka zituma ingirabuzima fatizo zifite kanseri zikura kandi zigakomeza kubaho.

Akenshi ikoreshwa mu kuvura kanseri y'ibihaha igeze kure cyangwa yateye.

5. Imiti igabanya ubukana bw'indwara: Ubu buryo bufasha abasirikare b'umubiri kumenya no kurwanya ingirabuzimafatizo za kanseri.

Akenshi ikoreshwa mu kuvura kanseri y'ibihaha igeze kure cyangwa yateye.

6. Ubuvuzi bwa Photodynamic: Ubu buryo bwo kuvura bukoresha umuti ukoreshwa n'urumuri kugira ngo wice ingirabuzimafatizo za kanseri.

Akenshi ikoreshwa mu kuvura kanseri y'ibihaha ikiri mu ntangiriro.

7. Proton therapy: ubu ni uburyo bwo kuvura hakoreshejwe imirasire yifashisha proton aho gukoresha imirasire ya X mu gutanga imirasire ku kibyimba.

Akenshi ikoreshwa mu kuvura kanseri y'ibihaha ikiri mu ntangiriro.

8. Gupima indwara: Abarwayi bashobora kwemererwa kwifatanya mu gupima indwara hakoreshejwe uburyo bushya bwo kuvura cyangwa uburyo bwo kuvura bukomatanyirijwe hamwe.

Ni ngombwa kuganira n'itsinda ry'abaganga ku buryo bwiza bwo kuvura, kuko uburyo bwiza bwo kuvura buzaterwa n'imimerere ya buri muntu.

['Ibitabo']

PubMed/Medline https://www.nlm.nih.gov/databases/download/pubmed_medline.html

RefinedWeb https://arxiv.org/abs/2306.01116

Chen JH, Wu J, Xu Q: The emerging treatment landscape of targeted therapy in non-small-cell lung cancer. Signal Transduct Target Ther. , 4 (): 61.

Furuse K: [Photodynamic therapy of centrally located early-stage lung cancer]. Gan To Kagaku Ryoho. 1996, 23 (1): 27-30.

Gálffy G: [From rare mutations to classical ones, inhibition of signaling pathways in non-small cell lung cancer]. Magy Onkol. 2020, 64 (3): 196-204.

Magalhães M, Alvarez-Lorenzo C, Concheiro A, Figueiras A, Santos AC, Veiga F: RNAi-based therapeutics for lung cancer: biomarkers, microRNAs, and nanocarriers. Expert Opin Drug Deliv. 2018, 15 (10): 965-982.

Kataoka M, Fujiwara T, Tanaka N: [Gene therapy for lung cancer]. Nihon Geka Gakkai Zasshi. 2002, 103 (2): 244-9.

Jin C, Yang B: A Case of Delayed Diagnostic Pulmonary Tuberculosis during Targeted Therapy in an EGFR Mutant Non-Small Cell Lung Cancer Patient. Case Rep Oncol. , 14 (1): 659-663.

Wang Y, Liu Q, Chen H, You J, Peng B, Cao F, Zhang X, Chen Q, Uzan G, Xu L, Zhang D: Celastrol improves the therapeutic efficacy of EGFR-TKIs for non-small-cell lung cancer by overcoming EGFR T790M drug resistance. Anticancer Drugs. 2018, 29 (8): 748-755.

['Icyitonderwa: ubuvuzi']

["Uru rubuga rwashyiriweho kwigisha abantu no kubaha amakuru gusa, ntirutanga inama ku birebana n'ubuvuzi cyangwa ngo rukore nk'ikigo gitanga serivisi z'ubuvuzi."]

["Amakuru atangwa n'iyi porogaramu ntagomba gukoreshwa mu gusuzuma cyangwa kuvura ikibazo cy'uburwayi cyangwa indwara runaka, kandi abashaka inama z'ubuvuzi bagombye kugisha inama umuganga ubifitiye uburenganzira."]

['Nyamuneka menya ko imbuga nkoranyambaga zitanga ibisubizo kubibazo, ntabwo zifite ukuri mugihe kijyanye numubare. Kurugero, umubare wabantu basanzwemo indwara runaka.']

["Buri gihe ujye usaba inama umuganga wawe cyangwa undi muntu wemewe mu bijyanye n'ubuzima ku bijyanye n'uburwayi. Ntuzigere wirengagiza inama z'abaganga cyangwa ngo utinde kuzisaba bitewe n'ikintu wasomye kuri uru rubuga. Niba utekereza ko ufite ikibazo cyihutirwa, hamagara 911 cyangwa ujye ku ivuriro rikwegereye. Nta mubano hagati y'umuganga n'umurwayi ukorwa n'uru rubuga cyangwa ikoreshwa ryarwo. Yaba BioMedLib cyangwa abakozi bayo, cyangwa undi muntu wese wagize uruhare kuri uru rubuga, nta gihamya batanga, yaba igaragara cyangwa itagaragara, ku bijyanye n'amakuru atangwa hano cyangwa ikoreshwa ryayo."]

["Ibirego: uburenganzira bw'umuhanzi"]

["Itegeko ryo mu 1998 ryerekeye uburenganzira bw'ibihumbi by'ibihumbi by'ibihumbi by'ibihumbi, 17 U.S.C. § 512 (DMCA) ritanga ubujurire ku bafite uburenganzira bw'umuhanzi bemera ko ibintu bigaragara kuri interineti bibangamira uburenganzira bwabo hakurikijwe amategeko y'uburenganzira bw'umuhanzi muri Amerika. "]

['Niba wemera ko ibintu cyangwa ibikoresho byashyizwe ku rubuga rwacu cyangwa serivisi bitubahiriza uburenganzira bwawe, wowe (cyangwa umuhagarariye) ushobora kutwoherereza ubutumwa udusaba ko ibyo bintu cyangwa ibikoresho bikurwaho, cyangwa ko utabikoresha.']

['Itangazo rigomba koherezwa mu nyandiko kuri interineti (reba ahanditse "Kwitaba" kugira ngo ubone aderesi ya interineti). ']

["DMCA isaba ko imenyesha ryawe ry'ikirego cyo kuvutswa uburenganzira rikubiyemo amakuru akurikira: (1) ibisobanuro by'igikorwa kirengera uburenganzira bw'umuhanzi kivugwaho kuvutswa uburenganzira; (2) ibisobanuro by'ibikubiyemo bivugwa ko ari ukurenga ku mategeko n'amakuru ahagije atuma dushobora kubona ibikubiyemo; (3) amakuru yo kuguhamagaraho, harimo aderesi yawe, nomero ya terefone na aderesi imeyiri; (4) inyandiko yawe ivuga ko ufite icyizere ko ibikubiyemo mu buryo bwatanzwe nta burenganzira bifite na nyiri uburenganzira bw'umuhanzi, cyangwa umukozi we, cyangwa mu mategeko ayo ari yo yose; "]

["(5) inyandiko yawe isinyweho, uhanishwa kubeshya, yemeza ko amakuru ari mu itangazo ari ukuri kandi ko ufite ububasha bwo kurengera uburenganzira bw'umuhanzi uvugwaho kubwamburwa; "]

["kandi (6) umukono usanzwe cyangwa wa elegitoroniki w'ufite uburenganzira ku nyandiko cyangwa uw'umuntu wabiherewe uburenganzira bwo gukora mu izina ry'ufite uburenganzira ku nyandiko. "]

['Kudatanga amakuru yose yavuzwe haruguru bishobora gutuma ikibazo cyawe gitinda gukemurwa.']

['Uko twavugana na we']

['Ohereza imeri ikibazo / igitekerezo.']

How to treat lung cancer?

The treatment for lung cancer depends on several factors, including the stage of the cancer, the type of lung cancer, and the patient's overall health.

Some common treatment options include:

1. Surgery: This is often the preferred treatment for early-stage lung cancer.

The surgeon removes the tumor and a small portion of healthy tissue around it.

2. Radiation therapy: High-energy radiation is used to kill cancer cells and shrink tumors.

It can be used alone or in combination with other treatments.

3. Chemotherapy: This treatment uses drugs to kill cancer cells.

It can be given intravenously or or orally, and is often used in combination with other treatments.

4. Targeted therapy: This treatment targets specific genes or proteins that contribute to the growth and survival of cancer cells.

It is often used for advanced or metastatic lung cancer.

5. Immunotherapy: This treatment helps the immune system recognize and attack cancer cells.

It is often used for advanced or metastatic lung cancer.

6. Photodynamic therapy: This treatment uses a light-activated drug to kill cancer cells.

It is often used for early-stage lung cancer.

7. Proton therapy: This is a type of radiation therapy that uses protons instead of x-rays to deliver radiation to the tumor.

It is often used for early-stage lung cancer.

8. Clinical trials: Patients may be eligible to participate in clinical trials testing new treatments or combinations of treatments.

It is important to discuss the best treatment options with a healthcare team, as the most effective treatment plan will depend on the individual's specific situation.

Disclaimer: medical

This web site is provided for educational and informational purposes only and does not constitute providing medical advice or professional services.

The information provided should not be used for diagnosing or treating a health problem or disease, and those seeking personal medical advice should consult with a licensed physician.

Please note the neural net that generates answers to the questions, is specially inaccurate when it comes to numeric content. For example, the number of people diagnosed with a specific disease.

Always seek the advice of your doctor or other qualified health provider regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. If you think you may have a medical emergency, call 911 or go to the nearest emergency room immediately. No physician-patient relationship is created by this web site or its use. Neither BioMedLib nor its employees, nor any contributor to this web site, makes any representations, express or implied, with respect to the information provided herein or to its use.

Disclaimer: copyright

The Digital Millennium Copyright Act of 1998, 17 U.S.C. § 512 (the “DMCA”) provides recourse for copyright owners who believe that material appearing on the Internet infringes their rights under U.S. copyright law. If you believe in good faith that any content or material made available in connection with our website or services infringes your copyright, you (or your agent) may send us a notice requesting that the content or material be removed, or access to it blocked. Notices must be sent in writing by email (see 'Contact' section for email address) . The DMCA requires that your notice of alleged copyright infringement include the following information: (1) description of the copyrighted work that is the subject of claimed infringement; (2) description of the alleged infringing content and information sufficient to permit us to locate the content; (3) contact information for you, including your address, telephone number and email address; (4) a statement by you that you have a good faith belief that the content in the manner complained of is not authorized by the copyright owner, or its agent, or by the operation of any law; (5) a statement by you, signed under penalty of perjury, that the information in the notification is accurate and that you have the authority to enforce the copyrights that are claimed to be infringed; and (6) a physical or electronic signature of the copyright owner or a person authorized to act on the copyright owner’s behalf. Failure to include all of the above information may result in the delay of the processing of your complaint.